<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Medicines on Homigin's Garden</title><link>https://homigin.github.io/medicine/</link><description>Recent content in Medicines on Homigin's Garden</description><generator>Hugo -- 0.146.0</generator><language>en</language><lastBuildDate>Fri, 18 Jul 2025 00:00:00 +0000</lastBuildDate><atom:link href="https://homigin.github.io/medicine/index.xml" rel="self" type="application/rss+xml"/><item><title>Harrison's</title><link>https://homigin.github.io/medicine/harrisons/</link><pubDate>Fri, 07 Feb 2025 00:00:00 +0000</pubDate><guid>https://homigin.github.io/medicine/harrisons/</guid><description>&lt;p>&lt;img alt="Harrison&amp;rsquo;s 21ed.pdf" loading="lazy" src="https://homigin.github.io/assets/harrison's_21ed_1706760046551_0.pdf">
page + 40&lt;/p>
&lt;h2 id="part-1-the-profession-of-medicine">Part 1 The profession of medicine&lt;/h2>
&lt;ul>
&lt;li>
&lt;h2 id="the-practice-of-medicine">The practice of medicine&lt;/h2>
&lt;ul>
&lt;li>
&lt;p>To wrest from nature the secrets which have perplexed philosophers in all ages, to track to their sources the causes of disease, to correlate the vast stores of knowledge, that they may be quickly available for the prevention and cure of disease—these are our ambitions.
—William Osler, 1849–1919&lt;/p>
&lt;/li>
&lt;li>
&lt;p>Jameson JL, Longo DL: Precision medicine—personalized, problem-
atic, and promising. N Engl J Med 372:2229, 2015.&lt;/p></description></item><item><title>NCS</title><link>https://homigin.github.io/medicine/ncs/</link><pubDate>Fri, 07 Feb 2025 00:00:00 +0000</pubDate><guid>https://homigin.github.io/medicine/ncs/</guid><description/></item><item><title>Stroke Prevention in Atrial Fibrillation</title><link>https://homigin.github.io/medicine/stroke-prevention-in-atrial-fibrillation/</link><pubDate>Mon, 01 Aug 2022 00:00:00 +0000</pubDate><guid>https://homigin.github.io/medicine/stroke-prevention-in-atrial-fibrillation/</guid><description>&lt;p>Attachments&lt;/p>
&lt;ul>
&lt;li>&lt;a href="https://vbn.aau.dk/ws/files/484295076/Chiang_et_al._2022_Stroke_Prevention_in_Atrial_Fibrillation.pdf">Chiang et al_2022_Stroke Prevention in Atrial Fibrillation.pdf&lt;/a> {{zotero-imported-file WAMDXZGJ, &amp;ldquo;Chiang et al_2022_Stroke Prevention in Atrial Fibrillation.pdf&amp;rdquo;}}&lt;/li>
&lt;/ul>
&lt;p>&lt;img alt="https://ars.els-cdn.com/content/image/1-s2.0-S2772374722001648-fx1_lrg.jpg" loading="lazy" src="https://ars.els-cdn.com/content/image/1-s2.0-s2772374722001648-fx1_lrg.jpg">&lt;/p>
&lt;h2 id="prevalence-of-af-in-asia">Prevalence of Af in Asia&lt;/h2>
&lt;ul>
&lt;li>亞洲台灣地區在2020年的 Afib 患病率約為1.5％，預計到2050年將達到4.0％。&lt;/li>
&lt;/ul>
&lt;p>亞洲的 Afib 患病率正在增加，可以使用多種評分方案（例如C2HEST 和 Taiwan AF scores）來預測亞洲患者發生房顫的風險。
&lt;img alt="https://ars.els-cdn.com/content/image/1-s2.0-S2772374722001661-gr1.jpg" loading="lazy" src="https://ars.els-cdn.com/content/image/1-s2.0-s2772374722001661-gr1.jpg">&lt;/p>
&lt;h2 id="assessmentre-assessment-of-stroke-and-bleeding-risks">Assessment/re-Assessment of Stroke and Bleeding Risks&lt;/h2>
&lt;ul>
&lt;li>
&lt;p>亞洲Afib 患者每年中風風險約為3.0%&lt;/p>
&lt;/li>
&lt;li>
&lt;p>對於亞洲房顫患者，我們建議使用CHA2DS2-VASc和HAS-BLED評分來評估中風和出血風險。&lt;/p>
&lt;/li>
&lt;li>
&lt;p>對於CHA2DS2-VASc評分男性≥1分，女性≥2分的亞洲房顫患者，應提供口服抗凝藥物。&lt;/p>
&lt;/li>
&lt;li>
&lt;p>患者年齡增長和併發症的發生會使中風和出血風險發生變化，因此，CHA2DS2-VASc和HAS-BLED評分應定期重新評估，最好在每次看門診時進行評估。&lt;/p>
&lt;ul>
&lt;li>亞太地區心律協會(APHRS)建議：中風風險應定期重新評估
（至少每年一次，如有可能，每4個月一次）。&lt;/li>
&lt;/ul>
&lt;/li>
&lt;li>
&lt;p>強調高HAS-BLED評分不應成為不給房顫患者處方或停用口服抗凝藥物的原因。&lt;/p>
&lt;ul>
&lt;li>
&lt;p>HAS-BLED評分≥3的 afib 患者，使用口服抗凝藥物與缺血性中風、顱內出血或死亡的綜合不良事件風險較低（4.19/100人年 vs 5.22/100人年，調整HR：0.781，P = 0.04）。&lt;/p>
&lt;/li>
&lt;li>
&lt;p>對於baseline HAS-BLED評分為0-2且增加到≥3的服用抗凝藥物的房顫患者，繼續使用口服抗凝藥物與更好的臨床結果相關。&lt;/p>
&lt;/li>
&lt;li>
&lt;p>HAS-BLED score 可以幫助醫生識別和糾正可改變的出血風險因素，對正在抗凝治療的房顫患者進行干預。&lt;/p>
&lt;/li>
&lt;/ul>
&lt;/li>
&lt;/ul>
&lt;h2 id="abc-pathway">ABC Pathway&lt;/h2>
&lt;p>&lt;img alt="https://ars.els-cdn.com/content/image/1-s2.0-S2772374722001661-fx1.jpg" loading="lazy" src="https://ars.els-cdn.com/content/image/1-s2.0-s2772374722001661-fx1.jpg">&lt;/p>
&lt;ul>
&lt;li>
&lt;p>ABC pathway - 較低的 all-cause death, cardiovascular death, stroke, and major bleeding 風險&lt;/p></description></item></channel></rss>